{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-091619","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2026-08-06T11:05:29+00:00","discovered_at":"2026-08-06T11:10:07.335831+00:00","generated_at":"2026-08-06T11:11:49.692746+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Iovance reports record Q2 revenue ~$99M (+66% YoY); reviewing FY26 guidance; FDA FTD for lifileucel in sarcomas","bullets":["Total product revenue ~$99M, up 66% from ~$60M in Q2 2025 and 39% from ~$71M in Q1 2026.","U.S. Amtagvi revenue ~$91M, up 40% from Q4 2025; gross margin improved to 56%.","Cash position ~$304M as of June 30, 2026, expected to fund operations into 2H28.","FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas (UPS/DDLPS); SARATOGA trial ORR 50% in first six patients.","Australia TGA approved Amtagvi MAA; UK MAA resubmitted for expedited review; FY26 revenue guidance of $350-370M under review."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-091619","json":"https://secwatch.observer/filing/0001104659-26-091619.json","markdown":"https://secwatch.observer/filing/0001104659-26-091619.md","text":"https://secwatch.observer/filing/0001104659-26-091619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/0001104659-26-091619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:11:49.692746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}